 |
|
Screening strategy for non-alcoholic fatty liver disease
Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto
Clin Mol Hepatol. 2023;29(Suppl):S103-S122. Published online 2022 Nov 30 DOI: https://doi.org/10.3350/cmh.2022.0336
|
|
Citations to this article as recorded by
 Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease
Heejoon Jang, Yeonjin Kim, Dong Hyeon Lee, Sae Kyung Joo, Bo Kyung Koo, Soo Lim, Woojoo Lee, Won Kim
JAMA Internal Medicine.2024; 184(4): 375. CrossRef Validation of a screening panel for pediatric metabolic dysfunction–associated steatotic liver disease using metabolomics
Helaina E. Huneault, Alasdair E. Gent, Catherine C. Cohen, Zhulin He, Zachery R. Jarrell, Rishikesan Kamaleswaran, Miriam B. Vos
Hepatology Communications.2024;[Epub] CrossRef Screening the General Population for Non-Alcoholic Fatty Liver Disease: Model Development and Validation
Tanya Mohammadi, Babak Mohammadi
Archives of Medical Research.2024; 55(3): 102987. CrossRef The associations between fibrosis changes and liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease
Hye Won Lee, Kun Hee Kim, Sang Hoon Ahn, Han Chu Lee, Jonggi Choi
Liver International.2024; 44(6): 1448. CrossRef Evaluation of the ability of insulin resistance and lipid-related indices to predict the presence of NAFLD in obese adolescents
Aylin Yetim, Memduh Şahin, İbrahim Kandemir, Betül Bulakçı, Melike Tuğrul Aksakal, Edanur Karapınar, Hayrettin Sever, Firdevs Baş
Lipids in Health and Disease.2024;[Epub] CrossRef Adolescent Metabolic Screening
Kirti Sivakoti
Primary Care: Clinics in Office Practice.2024; 51(4): 603. CrossRef Reference Range of Quantitative MRI Metrics Corrected T1 and Liver Fat Content in Children and Young Adults: Pooled Participant Analysis
Elizabeth Shumbayawonda, Cayden Beyer, Benito de Celis Alonso, Silvia Hidalgo-Tobon, Briceida López-Martínez, Miguel Klunder-Klunder, América Liliana Miranda-Lora, E. Louise Thomas, Jimmy D. Bell, David J. Breen, Kamil Janowski, Maciej Pronicki, Wieslawa
Children.2024; 11(10): 1230. CrossRef Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan
Clinical and Molecular Hepatology.2024; 30(4): 1039. CrossRef Non-Alcoholic Fatty Liver Disease, Awareness of a Diagnostic Challenge—A Clinician’s Perspective
Cristina Maria Marginean, Denisa Pirscoveanu, Sergiu Marian Cazacu, Marian Sorin Popescu, Iulia Cristina Marginean, George Alexandru Iacob, Mihaela Popescu
Gastroenterology Insights.2024; 15(4): 1028. CrossRef Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed
Philipp Kasper, Münevver Demir, Hans-Michael Steffen
Clinical and Molecular Hepatology.2023; 29(2): 390. CrossRef Regression of nonalcoholic fatty liver disease is associated with reduced risk of incident diabetes: A longitudinal cohort study
Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Sung Chul Choi, Yun Soo Hong, Yewan Park, Juhee Cho, Geum-Youn Gwak, Ahmed Mustafa Rashid
PLOS ONE.2023; 18(7): e0288820. CrossRef Non-alcoholic fatty liver disease – a challenging health problem of the 21st century
Anamaria Cozma-Petruţ, Lorena Filip , Doina Miere
Dietetician.ro.2023; 2(2): 30. CrossRef The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review
Teodora Biciusca, Sorina Ionelia Stan, Mara Amalia Balteanu, Ramona Cioboata, Alice Elena Ghenea, Suzana Danoiu, Ana-Maria Bumbea, Viorel Biciusca
Diagnostics.2023; 13(21): 3316. CrossRef Waiting for the changes after the adoption of steatotic liver disease
Eileen L. Yoon, Dae Won Jun
Clinical and Molecular Hepatology.2023; 29(4): 844. CrossRef Uncovering the Cardiovascular Threat: A Comprehensive Examination of Liver Fibrosis and Subclinical Atherosclerosis in Non-alcoholic Fatty Liver Disease
Niketa Sharma, Swarupa Chakole, Bhushan Wandile
Cureus.2023;[Epub] CrossRef Alcohol consumption and the risk of liver disease: a nationwide, population-based study
Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek
Frontiers in Medicine.2023;[Epub] CrossRef Nonalcoholic Fatty Liver Disease as a Systemic Disease and the Need for Multidisciplinary Care
Masato Yoneda, Takashi Kobayashi, Michihiro Iwaki, Asako Nogami, Satoru Saito, Atsushi Nakajima
Gut and Liver.2023; 17(6): 843. CrossRef MASLD and aspartame: are new studies in the horizon?
Consolato M. Sergi
Frontiers in Medicine.2023;[Epub] CrossRef Sessiz Epidemi: Metabolik Disfonksiyon İlişkili Karaciğer Yağlanması Hastalığının Önlenmesine ve Yönetilmesine Yönelik Güncel Yaklaşımlar
Ferya ÇELİK, Merve YÜKSEL, Hicran BEKTAŞ
Artuklu International Journal of Health Sciences.2023; 3(3): 343. CrossRef
|